MATHEMATICAL MODELING OF TYPE 1 DIABETES PROGRESSION IN THE NOD MOUSE: SEPARATING INCIDENCE AND AGE OF ONSET.

JAMES R. MOORE AND FRED ADLER

ABSTRACT. Type 1 diabetes (T1D) is an autoimmune disease of the β-cells of the pancreas. The nonobese diabetic (NOD) mouse is a commonly used animal model, with roughly an 80% incidence rate of T1D among females. In 100% of NOD mice, macrophages and T-cells invade the islets in a process called insulitis. It can be several weeks between insulitis and T1D, and some mice do not progress at all. It is thought that this delay is mediated by regulatory T-cells (Tregs) and that a gradual loss of effectiveness in this population leads to T1D. However, this does not explain why some mice progress and others do not. We propose a simple mathematical model of the interaction between β-cells and the immune populations, including regulatory T-cells. We find that individual mice may enter one of two stable steady states: a ‘mild’ insulitis state that does not progress to T1D and a ‘severe’ insulitis state that does. We then run a sensitivity analysis to identify which parameters affect incidence of T1D versus those that affect age of onset. We also test the model by simulating several experimental manipulations found in the literature that modify insulitis severity and/or Treg activity. Notably, we are able to match a reproduce a large number of phenomena using a relatively small number of equations. We finish by proposing experiments that could help validate or refine the model.

1. Introduction

1.1. Biological background. Type 1 diabetes (T1D) is an autoimmune disorder in which T-cells invade the islets of langerhans within the pancreas and kill insulin producing β-cells. The nonobese diabetic or NOD mouse is an inbred mouse strain that spontaneously develops T1D. Among females, the age of onset is on average 12-16 weeks, with an incidence of 60-80%. Prior to T1D onset, at 3-4 weeks of age, immune cells such as CD4 T-cells, CD8 T-cells, and macrophages invade the islets. This infiltration, called insulitis, gradually becomes more severe, affecting more islets and penetrating more deeply (see Figure 1). It is present in all NOD mice, even those that do not develop T1D.

NOD mice exhibit multiple immune problems. For an extensive review, see [5]. Here we focus on a few key differences from the wild type, which may mimic the factors that lead to genetic susceptibility in humans. First, there is a failure in central tolerance as NOD mice do not effectively present peptides from the proinsulin gene in the thymus. This leads to the generation of a population of proinsulin reactive lymphocytes, although these T-cells typically have a low affinity for their target T-cell antigen. These T-cells are the first detected in the pancreas during immunopathogenesis and eventually give way to other more reactive T-cell clones. However, the anti-proinsulin response appears to be required [11, 34]. In humans, T1D is associated with lower expression of insulin in the
Progression of insulitis in the islets. Over time, immune cells such as T-cells and macrophages infiltrate the islets, killing β-cells and decreasing insulin production.

Figure 1. Progression of insulitis in the islets. Over time, immune cells such as T-cells and macrophages infiltrate the islets, killing β-cells and decreasing insulin production.

- Second, NOD mice have a defect in the clearance of apoptotic cells. Specifically, this is a defect in macrophages, an antigen nonspecific immune cell with a large number of jobs, including the clearance of dead cells and the activation of T-cells. The excess apoptotic cells can become necrotic and trigger an inflammatory response by macrophages. This defect is particularly important at the time of weaning when the pancreas undergoes structural changes and heightened apoptosis. This apoptotic wave and subsequent inflammation initiates an immune response, and T-cells start to infiltrate the pancreas (see Table 1). Finally, NOD mice have a defect in the growth and survival factor IL-2. Despite its role as a T-cell growth factor, deficiency in IL-2 typically leads to uncontrolled growth of effector T-cells as IL-2 is required for the proliferation and survival of Tregs. Tregs can control the development of T1D in the NOD mouse for several months, and T1D is greatly accelerated in Treg-deficient NOD mice. Human T1D patients have impaired IL-2 signaling via a defect in the high affinity IL-2 receptor.

It is unclear what causes T-cells to escape the regulation of Tregs and destroy β-cells. The simplest hypothesis is that the destruction of β-cells within the islets is ongoing, but that T1D is not diagnosed until the β-cell mass reaches a critical level. However,
Table 1. T1D progression in the NOD mouse

| Time     | Event                                             | Source |
|----------|---------------------------------------------------|--------|
| 9-15 days| Apoptotic Wave                                    | 30     |
| 18 days  | T1D in Treg deficient NOD mice                    | 6      |
| 3 weeks  | Initiation of Insulitis                           | 12     |
| 4-5 weeks| Insulin-specific CD8s dominate                     | 29     |
| 4-5 weeks| Rapid T1D after ablation of Tregs                 | 8      |
| 6 weeks  | Differential Prognosis with MRI                   | 12     |
| 6-8 weeks| Decline in Treg effectiveness                     | 28     |
| 8 weeks  | IGRP-specific CD8s appear                          | 29     |
| 8-12 weeks| $\beta$-cell mass starts to decline               | 2      |
| 12-16 weeks| Rapid loss of $\beta$-cell mass                   | 2      |
| 16 weeks | Median T1D onset                                   | 4      |

Quantification of the $\beta$-cell mass shows that it does not start to decline until 8-12 weeks of age [2], 6-10 weeks after the apoptotic wave [30]. Ablation of Tregs in 4-6-week old mice leads to rapid T1D onset [8], indicating that Tregs are required to prevent disease progression. This suggests that Tregs possibly lose effectiveness over time. This hypothesis is supported by the work of Tritt et al. [28], who find that older mice have similar numbers of Tregs, but they are less able to control T1D than those of young adult mice, and Pop et al. [22], who find that Tregs from older mice have a loss of function in vitro. Another possibility is that $\beta$-cells gradually lose function over time. It may be that the $\beta$-cells degranulate, losing their ability to produce insulin, [1] or simply apoptose [14, 27] in response to increased demands. Finally, the delay may be due to the time it takes for the development of a population of T-cells capable of killing $\beta$-cells. In the early stages of insulitis, the most important population of T-cells is CD4s, or helper T-cells, which can activate other components of the immune system, but not directly kill target cells. Another population of T-cells, CD8s or killer T-cells, is very efficient at killing target cells, but require additional activation. In the early stages of T1D in NOD mice, the CD8 population is generally insulin-specific with a low affinity. After several weeks, high affinity CD8s, specific to islet-specific glucose-6-phosphate catalytic subunit related protein (IGRP), take their place. The destruction of $\beta$-cells corresponds to the expansion of this population [4].

Almost all NOD mice develop insulitis, and yet many do not develop T1D. Trudeau et al. [29] find significant differences in the makeup of the CD8 T-cell population between those that get T1D and those that do not. In particular, CD8 T-cells specific for the islet antigen IGRP are at much higher levels in the ‘prediabetic’ mice, although they do not appear until week 8 in either group [29]. Fu et al. [12] perform MRIs of mice at different ages and find that the degree of inflammation is significantly greater in the mice destined for T1D. At 6 weeks, inflammation of the pancreas is significantly correlated with the eventual development of T1D. They also find that the mice with lower inflammation expressed higher levels of CR1g, a marker of a class of regulatory macrophages. Taken together, these studies suggest that the eventual fate of an individual mouse is predetermined at the initiation of insulitis. The nature of the insulitis of each mouse should therefore fall
into at least two classes, which can be distinguished by the presence of CR1g-expressing macrophages. Islets with more severe inflammation have a greater level of $\beta$-cell turnover and therefore a greater presentation of IGRP. This ultimately leads to a greater IGRP CD8 response and T1D.

1.2. Prior modeling. As discussed above, the initiation of T1D requires a proinflammatory stimulus, which, in the NOD mouse, likely occurs during weaning. Nerup and colleagues [21] propose a nonmathematical description of T1D initiation, the ‘Copenhagen Model’, which is not specific to NOD mice. The stimulating event, such as a virus, causes minor $\beta$-cell destruction and, more importantly, releases $\beta$-cell antigens triggering an immune cascade. De Blasio et al. [7] proposed a simple model of 4 ODEs (resting and activated macrophages, $\beta$-cell antigen and T-cells) to reproduce this phenomenon. The model is intentionally generic and does not describe any particular environmental insult. They find that the activity of Macrophages is key and that the nature of the T-cell response does not drive inflammation. Maree et al. [20] expanded upon this model and incorporated the ideas of Trudeau [30]: that NOD mice have a reduced ability to clear apoptotic $\beta$-cells that then become necrotic. They find that for NOD mice, the system is bistable; the wave of apoptosis transfers the system from a resting ‘healthy’ state to a ‘disease’ state.

Regulatory T-cells play an important role of slowing the progression of T1D and other autoimmune diseases. Alexander et al. [3] study a generic model of the Treg-controlled autoimmune disease. They demonstrate that Tregs may not eliminate an autoimmune response, but can reduce it to a subclinical level. Similarly, Magombdze et al. incorporate Treg control into the framework of the Copenhagen/Maree models and find that Tregs cannot eliminate the autoimmune response, but can reduce its intensity so that the $\beta$-cell population is barely affected.

Leah Keshet and colleagues have investigated the dynamics of the CD8 population in a series of papers. The time series of the IGRP CD8 population in [29] appears cyclical. Mahaffy, Keshet et al. [19] model this phenomenon using multiple T-cell compartments: ‘activated’ T-cells can become either effectors and memory cells (which can later become activated upon restimulation). Their model reproduces the observed cycle and the $\beta$-cells die off step-wise during each cycle until none remain. Khadra, Keshet et al. [17] investigate the competition between low-affinity and high-affinity CD8s. High-affinity CD8s kill $\beta$-cells, releasing antigens and perpetuate the immune response, whereas low-affinity CD8s simply crowd the environment. This leads, fairly robustly, to a bistable system that has a ‘healthy’ state with few high-affinity CD8s and a ‘diseased’ state with many.

1.3. Outline of our approach. We seek a simple model that

(1) has two possible outcomes, a ‘T1D’ state and an ‘insulitis but no T1D’ state;
(2) develops T1D predominantly within a narrow time window; and
(3) is initially under the control of a Treg population, which it subsequently escapes.

We propose a model of T1D development that proceeds in two stages. An ‘initiation’ phase corresponding to the development-driven apoptosis and a ‘progression’ phase describing the increase in the number and reactivity of the islet-specific CD8 population. The initiation phase has two distinct outcomes corresponding to distinct stable equilibria:
mild-insulitis, which does not lead to progression, and severe-insulitis, which does. These two states are characterized by differences in the makeup of the macrophage population, the ratio of infiltrating Tregs to effector T-cells, and the cytokine milieu of the islet. We show how various treatments can shift the system from the severe insulitis state to the mild. The ‘progression’ phase is a feedforward model. Activated macrophages stimulate the growth of the CD8 population, which in turn kill β-cells causing a rise in blood glucose. Only in the severe insulitis state do the activated macrophages promote a sufficient growth in CD8 cells to promote T1D development.

We then validate this model by simulating various treatments of NOD mice found in the literature and comparing the results. To replicate incidence data, we must have heterogeneity in the mouse population. We generate this heterogeneity by changing the initial number of activated macrophages and the death rate due to CD8s, which we assume are quite variable. The justification for this is that they are the result of complicated processes (see [20] and [17], respectively) that can have multiple outcomes in otherwise identical organisms. We add a small amount of noise to all other parameters. We then perform a sensitivity analysis to investigate which parameters are key for the development of T1D. Specifically, we are interested in those that lead to an acceleration or delay of T1D versus those that change the incidence. Finally, we propose some further extensions and some possible experiments to further validate the model.

2. The initiation model

2.1. Activation of macrophages. Macrophages are among the first cells to infiltrate the islet in NOD mice [16], likely in response to an apoptotic wave of β-cell death during weaning (the ‘apoptotic wave’, see [30]). As explored in [20], NOD macrophages are inefficient at clearing these apoptotic cells, which leads to further inflammation and β-cell death. Here, we shall assume that the apoptotic wave has just passed, resulting in an initial excess of macrophages.

Tissue-resident macrophages are a type of innate immune cell, meaning non-antigen-specific, with an incredibly wide array of potential behaviors. They phagocytose other cells, act as antigen presenting cells (APCs) and control the behavior of neighboring cells, both immune and nonimmune, via the release of cytokines. They are critical in the initiation and continuation of immune responses and yet they can also act as ‘custodians’, clearing away debris from dead cells. These regulatory activities correlate with the expression of the receptor CRIg on a macrophages surface. CRIg expression is promoted by the regulatory molecule IL-10 and inhibited by the inflammatory molecule IFN-γ as well as other inflammatory molecules such as arachidonic acid [13]. Importantly, the expression of CRIg by pancreatic macrophages is negatively correlated with the progression to T1D [12]. Both IL-10 and IFN-γ are cytokines: diffusing, extracellular molecules used for communication between cells, typically of the immune system.

We assume there are two classes of Macrophage: inflammatory macrophages (M∗), corresponding to low CRIg expression, which can stimulate the activation and proliferation of T-cells, and regulatory macrophages (M), corresponding to high CRIg expression which act primarily as phagocytes. Macrophages can switch back and forth in response to external signals from cytokines. All macrophages enter the pancreas at a rate J in the
regulatory class. They activate to become inflammatory at a basal rate $a_0$, but their activation rate can be greatly enhanced by IFN-γ. Likewise, inflammatory macrophages deactivate at a basal rate $b_0$, and their deactivation rate is enhanced by IL-10.

\[
\frac{dM^*}{dt} = aM - bM^* - \delta M^* \\
\frac{dM}{dt} = J - aM + bM^* - \delta M \\
\]

\[
a = a_\gamma \frac{I_\gamma^2}{k_\gamma^2 + I_\gamma^2} + a_0 \\
b = b_{10} \frac{I_{10}^2}{k_{10}^2 + I_{10}^2} + b_0
\]

IFN-γ is produced by TH1 effector CD4 T-cells ($T$) in response to IL-12, a product of inflammatory macrophages. We let $T^*$ denote the population of effector T-cells expressing IFN-γ. IL-10 is produced by CD4 Tregs ($R$). Pancreatic Tregs in NOD mice overexpress IL-10, so we assume that the entire population expresses IL-10 without the need for further stimulation.

\[
\frac{dT^*}{dt} = c \frac{I_{12}^2}{k_{12}^2 + I_{12}^2} (T - T^*) - eT^* \\
\frac{dI_\gamma}{dt} = \alpha_\gamma T^* - \omega_\gamma I_\gamma \\
\frac{dI_{12}}{dt} = \alpha_{12} M^* - \omega_{12} I_{12} \\
\frac{dI_{10}}{dt} = \alpha_{10} R - \omega_{10} I_{10},
\]

where $c$ is the rate at which T-cells are activated by IL-12 and $e$ is the rate at which they revert to resting. Cytokine $i$ is produced at a rate $\alpha_i$ and decays at rate $\omega_i$. We assume that all cytokine concentrations equilibrate rapidly. Therefore, we set (3)-(4) equal to zero, and solve for the equilibrium concentrations. This yields the three-dimensional ODE:

\[
\frac{dM^*}{dt} = -\delta M M^* + (a_\gamma F(\nu_\gamma T^*) + a_0) M - (b_{10} F(\nu_{10} R) + b_0) M^* \\
\frac{dM}{dt} = J - \delta M M - (a_\gamma F(\nu_\gamma T^*) + a_0) M + (b_{10} F(\nu_{10} R) + b_0) M^* \\
\frac{dT^*}{dt} = c F(\nu_{12} M^*)(T - T^*) - eT^*
\]

where

\[
F(x) = \frac{x^2}{x^2 + 1} \\
\nu_i = \alpha_i / \omega_i k_i.
\]
2.2. Analysis of equilibria. The equilibria of (5) are given by

\[ T^* = C(M^*_eq)T = \frac{cF(\nu_{12}M^*_eq)}{e + cF(\nu_{12}M^*_eq)}T \]

\[ M = \frac{J}{\delta M} - M^*_eq \]

\[ M^* = M^*_eq \]

where \( M^*_eq \) satisfies

\[ M^*_eq = \frac{J}{\delta D} \frac{A(M^*_eq, T)}{\delta D + B(R) + A(M^*_eq, T)} \]

(6)

\( A(M^*_eq, T) = a_\gamma F(\nu_\gamma TC(M^*_eq)) + a_0 \)

\( B(R) = b_10 F(\nu_{10}R) + b_0 \).

(6) represents a fifth degree polynomial, whose coefficients alternate signs. Therefore we expect it to have 1, 3, or 5 positive real roots. For any parameter choice, the number and value of these equilibria will depend on the state variables \( T \) and \( R \), whose dynamics are discussed in the next section.

With our parameter values (see Table 3.2) there are either 1 or 3 solutions, depending on the values of \( T \) and \( R \). For fixed \( R \) and small values of \( T \), as in Figure 2A, there is only one solution with few inflammatory macrophages. This agrees with the observation that CD4s are required for the initiation of T1D [5]. There is also only one solution for large values of \( T \), corresponding to large numbers of inflammatory macrophages. For intermediate values of \( T \), there is both the inflamed and noninflamed solutions, separated by an unstable threshold solution.

![Figure 2. Equilibria of (5) with the parameters in Table 3.2.](image-url)
| Parameter | Description | value |
|-----------|-------------|-------|
| \( J \) | Influx of macrophages into pancreas | \( 1 \times 10^6 \) cells |
| \( \delta \) | Turnover of macrophages in pancreas | 1 days\(^{-1} \) |
| \( a_0 \) | Basal macrophage activation rate of macrophages | .05 days\(^{-1} \) |
| \( a_\gamma \) | Macrophage activation rate induced by IFN-\( \gamma \) | 8 days\(^{-1} \) |
| \( b_0 \) | Basal macrophage deactivation rate | .4 days\(^{-1} \) |
| \( b_{10} \) | Macrophage deactivation rate induced by IL-10 | 8 days\(^{-1} \) |
| \( e \) | CD4 activation rate by IL-12 | 8 days\(^{-1} \) |
| \( e \) | CD4 deactivation rate | 5.5 days\(^{-1} \) |
| \( \nu_\gamma \) | Scaled IFN-\( \gamma \) affinity of macrophages | \( 2\xi/J \) |
| \( \nu_{10} \) | Scaled IL-10 affinity of macrophages | \( \xi/J \) |
| \( \nu_{12} \) | Scaled IL-12 affinity of CD4 T-cells | \( \xi/J \) |
| \( \alpha_T \) | Influx of effectors into islets | \( 0.7 \times 10^6 \) cells |
| \( \alpha_R \) | Influx of Tregs into islets | \( 0.3 \times 10^6 \) cells |
| \( \gamma_T \) | Proliferation rate of effectors | 2 days\(^{-1} \) |
| \( \gamma_R \) | Proliferation rate of Tregs | 2 days\(^{-1} \) |
| \( \sigma_T \) | Max fraction of effectors in mitosis | .4 |
| \( \sigma_R \) | Max fraction of Tregs in mitosis | .8 |
| \( \delta_{T1} \) | Basal death rate of Tregs in pancreas | .2 days\(^{-1} \) |
| \( \delta_{T2} \) | Death rate of Tregs due to IL-2 deficiency | .8 days\(^{-1} \) |
| \( k_R \) | Scaled affinity of Tregs for IL-2 | \( 5\xi/J \) |
| \( \kappa_T \) | Scaled affinity of effectors for IL-2 | \( \xi/J \) |
| \( \alpha_C \) | Production of CD8s | .03 |
| \( \gamma_C \) | Division rate of CD8s | .27 |
| \( \delta_{C1} \) | Death rate of CD8s | .01 |
| \( \delta_{C2} \) | Autoregulation rate of CD8s | \( 2.6 \times 10^{-6} \) cells\(^{-1} \) days\(^{-1} \) |
| \( k_C \) | Saturation constant for CD8 proliferation | \( 0.75 \xi \) |
| \( \eta_4 \) | Rate of \( \beta \)-cell killing by CD4 | .3 |
| \( s_{T4} \) | Saturation constant of CD4 killing | 1 |
| \( s_{R4} \) | Control of Tregs over CD4 killing | 30 |
| \( \eta_8 \) | Per capita rate of beta cell killing by CD8 | \( 3.2 \times 10^6 \) cells |
| \( \gamma_B \) | Growth rate of beta cells | .06 |
| \( G_{hb} \) | Glucose level for half maximal beta cell growth | 161 |
| \( \delta_B \) | Death rate of beta cells | 1/60 |
| \( R_0 \) | Average glucose production | 864 mg days\(^{-1} \) |
| \( E_{G0} \) | Basal glucose decay rate | 1.44 days\(^{-1} \) |
| \( S_I \) | Rate of insulin-mediated glucose uptake | \( .72 \) days\(^{-1} \)/per \( \mu U \) |
| \( \sigma_I \) | Max insulin production rate | 43.2 \( \mu U \) days\(^{-1} \)/per mg |
| \( \delta_I \) | Insulin decay rate | 432 days\(^{-1} \) |
2.3. **Tregs and effectors compete in the islet.** During the progression of T1D, T-cells infiltrate the pancreatic islets. Cytotoxic CD8 T-cells directly kill β-cells, but the CD4 population also plays a role by maintaining an inflammatory environment that perpetuates the immune response. The CD4 population, also called helper T-cells, is often divided into two broad categories: effector T-cells and regulatory T-cells, which respectively promote or obstruct immune responses. T1D does not develop in NOD mice in the absence of CD4 effectors. With effectors present but not Tregs, the disease develops much faster, indicating that they also play an important role [6].

Effectors and Tregs enter the islet at a rate of $\alpha_T$ and $\alpha_R$, respectively. Although there are other populations of antigen presenting cells in the pancreas, we assume that T-cells are dependent upon interaction with macrophages in order to proliferate. This is equivalent to assuming that other APC population numbers are correlated with those of inflammatory macrophages. The maximum per-capita growth rate should therefore occur when there are very few T-cells relative to macrophages as the competition for binding space will be minimal. The decrease in proliferation rate as T-cell numbers increase has been observed in vivo [26]. For simplicity, we model this process as a Michaelis-Menten rate with the inflammatory macrophage acting analogously to an enzyme. We let $\sigma$ denote the maximum proportion of T-cells undergoing mitosis and $\gamma$ denote the exponential growth rate of those dividing cells. The maximum possible growth rate of the T-cell population is therefore $\gamma \sigma$.

The IL-2-BCL-2 pathway controls apoptosis of T-cells in the islets [26]. Secreted IL-2 promotes the expression of the antiapoptotic factor BCL-2 in T-cells. Tregs are dependent upon effectors for IL-2, whereas effectors are self sufficient. NOD mice are deficient in IL-2, leading to increased turnover in Tregs but not effectors [26]. Therefore, we assume that T-cells die at a constant rate $\delta_1$ but that Tregs will die at an enhanced rate $\delta_1 + \delta_2$ in the absence of IL-2. Effectors secrete IL-2 at a rate $\alpha_2$ and it is taken up by Tregs at a rate $\omega_2$. In addition, we include an input $u(t)$ representing IL-2 treatment.

\[
\begin{align*}
\frac{dT}{dt} &= \alpha_T + \gamma_T \frac{\sigma_T M^* T}{M^* + \sigma_T T + \sigma_R R} - \delta_1 T \\
\frac{dR}{dt} &= \alpha_R + \gamma_R \frac{\sigma_R M^* R}{M^* + \sigma_T T + \sigma_R R} - \left( \delta_1 + \delta_2 + \frac{k}{k + I_2} \right) R \\
\frac{dI_2}{dt} &= \alpha_2 T - \delta_2 I_2 - \omega_2 I_2 R + u(t)
\end{align*}
\]

Putting the cytokine concentration in steady state,

\[
\begin{align*}
\frac{dT}{dt} &= \alpha_T + \gamma_T \frac{\sigma_T M^* T}{M^* + \sigma_T T + \sigma_R R} - \delta_1 T \\
\frac{dR}{dt} &= \alpha_R + \gamma_R \frac{\sigma_R M^* R}{M^* + \sigma_T T + \sigma_R R} - \left( \delta_1 + \delta_2 \frac{k_R R + 1}{Q(t) + k_T T + k_R R + 1} \right) R
\end{align*}
\]

where $Q(t) = u(t)/k\delta_2$ is the scaled IL-2 treatment, $k_T = \alpha_2/k\delta_2$ the scaled IL-2 production rate and $k_R = \omega_2/\delta_2$ the scaled uptake by Tregs. Equation 7 and 5 together make up the initiation model.
2.4. **Analysis of the initiation model.** To simplify the analysis of this model, we consider the case $\alpha_T = \alpha_R = 0$ with $Q(t) = Q$. The system (7) then becomes

\[
0 = \gamma_T \frac{\sigma_T M_{eq}^* T}{M_{eq}^* + \sigma_T T + \sigma_R R} - \delta T_1 T,
\]

\[
0 = \gamma_R \frac{\sigma_R M_{eq}^* R}{M_{eq}^* + \sigma_T T + \sigma_R R} - \left( \delta_T + \delta_{T2} \frac{k_R R + 1}{Q + k_T T + k_R R + 1} \right) R,
\]

which has four solution branches: the trivial solution $T_0 = R_0 = 0$, a ‘$T$-only’ solution with

\[
T_1 = \frac{\gamma_T \sigma_T - \delta T_1}{\sigma_T \delta T_1} M_{eq} \tag{8}
\]

\[
R_1 = 0 \tag{9}
\]

an ‘$R$-only’ solution satisfying

\[
T_2 = 0 \tag{10}
\]

\[
0 = \gamma_R \frac{\sigma_R M_{eq}^*}{M_{eq}^* + \sigma_T T_3 + \sigma_R R_3} - \left( \delta_T + \delta_{T2} \frac{k_R R_2 + 1}{Q + k_T T_3 + k_R R_3 + 1} \right) \tag{11}
\]

and a ‘coexistence’ solution satisfying

\[
0 = \gamma_T \frac{\sigma_T M_{eq}^*}{M_{eq}^* + \sigma_T T_3 + \sigma_R R_3} - \delta T_1 \tag{12}
\]

\[
0 = \gamma_R \frac{\sigma_R M_{eq}^*}{M_{eq}^* + \sigma_T T_3 + \sigma_R R_3} - \left( \delta_T + \delta_{T2} \frac{k_R R_3 + 1}{Q + k_T T_3 + k_R R_3 + 1} \right) \tag{13}
\]

Each of these solutions exist for $\alpha_T, \alpha_R > 0$; however, only the coexistent solution is guaranteed to remain positive. The other three solutions are positive if and only if they are stable. Recalling that $M_{eq}^*$ represents the solution of a 5th degree polynomial whose coefficients depend on $T$ and $R$, we cannot directly solve this system. However, if we view $M_{eq}^*$ as a parameter, we can implicitly solve for $R, T$ and a parameter of our choice to create bifurcation diagrams.

First we vary $k_T$ (Figure 3A) to simulate different levels of IL-2 production by NOD mice. At the current parameter values (left dotted line), there are two stable equilibria: severe ($M_1^*$) and mild ($M_2^*$) insulitis. As $k_T$ increases, the severe equilibrium disappears. This is observed in [23], when a wild type IL-2 gene bred into the NOD mice greatly reduces T1D.
Figure 3. Bifurcation diagrams (A: $k_T$, B: $Q$, and C: $\sigma_T$ and $\sigma_R$ simultaneously) of the initiation model. Solid lines are stable states and dashed lines are unstable saddles. Black curves indicate that effectors and Tregs coexist, blue curves have only effectors, red curves only Tregs, and green curves represent the trivial solution. The arrows indicate the trajectory during IL-2 treatment (B) and anti-CD3 treatment (C). Dotted lines mark the baseline values in Table 3.2 and the locations of saddle-node bifurcations.
Next we increase $Q$ (Figure 3B) to simulate exogenous IL-2 treatment. The effect is similar to increasing $k_T$, except that the lower solution branch undergoes a transcritical bifurcation (red region) and switches to the $R$-only equilibrium. The arrows indicate, conceptually, the trajectory of the system during treatment. The trajectory starts on the upper branch, but is forced down onto the lower one after the saddle-node bifurcation. After treatment, the trajectory remains on the lower branch.

Finally, we vary $\sigma_R$ and $\sigma_T$ simultaneously while keeping them in the same proportion (Figure 3C). This represents treatment with anti-CD3 (which actually decreases these values to zero). The result is almost exactly the same as treatment with IL-2, with the trajectory dropping down onto the lower branch after the saddle-node bifurcation. Even though this branch is on the $T$-only equilibrium initially (blue region), it eventually undergoes a transcritical bifurcation to arrive at the mild insulitis equilibrium.

2.5. Parameter estimation. The typical lifespan of a macrophage within the pancreas is 10 days, so we let $\delta = 0.1$ days$^{-1}$ [20]. The concentration of these cells in the inflamed pancreas is $1 \times 10^7$ cell/ml, which we then take to be $J/\delta$, the total number of macrophages in our model at equilibrium [20]. The macrophage deactivation rate is $b_0 = 0.4$ [20]. We assume that $\alpha_T + \alpha_R$ has a similar magnitude to the macrophage influx $J$. From [26], we see that Tregs initially account for 30% of the CD4 population. Therefore, we let $\alpha_R = 0.3J$ and $\alpha_T = 0.7J$. From [32], we note that IL-12 triggers IFN-$\gamma$ after roughly 8 hours, and so we assume that $a_\gamma = c = 8$ days$^{-1}$. Also from [32], the half life of the expression of IFN-$\gamma$ is about 3 hrs, so $e = 5.5$ days$^{-1}$.

Initially, we let $\nu_{12} = \nu_{10} = \nu_\gamma = \delta/J$. This is so that the argument passed to $F$ would be close to 1, and so its sigmoidal behavior would be relevant. We find that with these parameters, the basin of attraction of the severe insulitis state is so small that the equilibrium cannot be reached from reasonable initial conditions. Doubling the value of $\nu_\gamma$ resolves this.

We let $\gamma_T = \gamma_R = 2$, which corresponds to a doubling time of 8 hours. We can directly observe $\sigma_T \approx 0.4$ and $\sigma_R \approx 0.8$ from the proliferation data in [26]. We also note that, at equilibrium, roughly 10% of effectors are dividing. Assuming that the proliferation rate matches the death rate at this point, we find that $\delta_{T1} = 0.2$. To fit the final parameters, we note that at equilibrium, roughly 20% of Tregs are dividing and that the ratio of Tregs to effectors is about 9 to 1 [26]. Taken together, this allows us to fit the parameters $\delta_{T2} = 0.8$, $k_T = 5\delta/J$ and $k_R = 20\delta/J$.

3. The progression model

3.1. CD8 T-cells. NOD mice have multiple lineages of islet specific T-cells, however, we focus on the high affinity IGRP/NRP-specific subset. We assume that these cells are generated at a low frequency due to control by central tolerance, but that they proliferate when the islet antigen IGRP is presented with costimulation in either the Pancreatic Lymph Node or the islets themselves. Following [19], we use both a linear death term,
representing normal turnover, and quadratic death term, representing autoregulation by
the CD8 population.

\[
\frac{dC}{dt} = \alpha C + \left( \gamma C \frac{M^*}{M^* + k_C} - \delta C_1 \right) C - \delta C_2 C^2
\]  
(14)

To parameterize this system we use the data for NRP-A7 CD8 T-cells in [4]. Assuming
that \( \alpha C \) is small and that \( M^* \) is constant from week 5 onwards. Then (14) becomes

\[
\frac{dC}{dt} \approx A_i C - \delta C_2 C^2
\]  
(15)

\[
A_i = \gamma C \frac{M^*_i}{M^*_i + k_C} - \delta C_1
\]  
(16)

Where \( A_i \) represents the exponential growth rate of CD8 population when \( M^* = M^*_i \).
From the time series data, we can estimate that \( \delta C_2 = 2.6 \times 10^{-6} \text{cells}^{-1}\text{days}^{-1} \) and \( A_2 = .13 \text{days}^{-1} \). From [29], we know that there are roughly 8 times as many NRP specific CD8 in mice that get T1D versus those that do not. This implies that \( A_2 \approx 8 \times A_1 \). Taken together, these two relations allow us to estimate the values of \( \gamma C = .27 \text{days}^{-1} \) and \( k_C = .75J \). Finally, \( \alpha_C \) remains as an important parameter controlling the timing of the
expansion of the CD8 T-cells. We adjust \( \alpha_C \), after assigning all other parameters, so that
the median onset of T1D occurs at 16 weeks. This gives \( \alpha_C = .03 \text{cells per day} \).

3.2. Metabolic subsystem. In most experiments, a T1D diagnosis corresponds to a
blood glucose level 250mg/dl (normal is 100mg/dl). Glucose controls both the proliferation rate and insulin production of beta cells. The produced insulin, in turn, stimulates the uptake of blood glucose. Topp et al. [27] modeled the insulin-glucose system with the following differential equations.

\[
\frac{dG}{dt} = R_0 - (E_{G0} - S_I I)G
\]  
(17)

\[
\frac{dI}{dt} = \sigma I \frac{B G^2 + G^2}{G^2 + G^2} - \delta_I I
\]  
(18)

As, \( \delta_I \gg 1 \), we assume that the insulin level \( I \) is in equilibrium.

\[
\frac{dG}{dt} = R_0 - \left( E_{G0} + \frac{S_I \sigma I B}{\delta_I} \frac{G^2}{G^2 + G^2} \right) G
\]  
(19)

To account for the increase in proliferation, we follow the work of [14] who created a highly detailed model of beta cell function. We simplify their model as

\[
\frac{dB}{dt} = \left( \gamma_B \frac{G^2}{G^2 + G^2_{hb}} - \delta_B \right) B
\]  
(20)

To parameterize this model we note the following. First, we observe from [24] that the number of proliferating cells reaches roughly 3%. This corresponds to a max growth rate \( \gamma_B = .06 \). The lifespan of a typical beta cell is 60 days [14] so \( \delta_B = 1/60 \). The resting population of \( \beta \)-cells in the absence of an immune response is \( B^* = 300 \), allowing us to solve for \( G_{hb} = 161mg/dl \).
In [15], untreated mice experience an increase in blood glucose from 300mg/dl to 500mg/dl in the first 2 weeks after onset. This corresponds to a decrease in β-cell mass from 24 to 4.32 in our model, a loss of roughly 12% daily. To offset compensatory growth, the immune response must remove about 16% of β-cells daily. In treated mice, on the other hand, glucose levels drop to about 200mg/dl, which is still twice the baseline level. In our model, we can only account for this by a continued immune destruction of about 2% of immune cells daily. This means that the strength of the immune response is roughly 8 times less after treatment than before. Interestingly, this prediction corresponds closely to the ratio of NRP-reactive cells found in [29] between mice that get T1D and those that do not. Taken together, we conclude that we can model β-cell death due to CD8s as mass action with a constant of $\eta_8 = 3.2 \times 10^{-6}$ cells$^{-1}$days$^{-1}$.

CD4s can also kill β-cells, although this primarily happens in the absence of Tregs. We include a killing term due to CD4s, which only becomes relevant to model behavior if Tregs are either absent [6] or removed [8]. Our final β-cell equation is

$$\frac{dB}{dt} = \left(\gamma_B \frac{G^2}{G^2 + G_{hb}^2} - \delta_B - \eta_8 C - \eta_4 \frac{(s_{T4}T^*)^2}{1 + (s_{T4}T^*)^2 + (s_{R4}R^*)^2}\right) B.$$  

4. Simulating treatments

In the next section, we simulate the treatments described in various papers. Table 3 summarizes the nature and duration of these treatments. Here we describe the implementation of IFN-α treatment, anti-CD3 antibodies (aCD3 treatment), anti-PDL1 antibodies (aPDL1 treatment), Treg treatment, and IL-2 treatment.

| Treatment            | Change                  | Timeframe         |
|----------------------|-------------------------|-------------------|
| IFN-α Treatment      | Day 63-77               | Set $\gamma_C = \nu_{12} = 0$ |
| Boost of Tregs       | Day 77-78               | Increase $\alpha_T$ by 15$\delta/J$ |
| anti-CD3 Treatment   | Day 35-49               | Set $\sigma_T = \sigma_R = \delta_{T2} = 0$ and $\delta_{T1} = 1$ |
| anti-PDL1 Treatment  | Day 119-133             | Set $\gamma_C = \gamma_T$ and $\nu_{12} = 20\delta/J$ |
| IL-2 treatment       | Every two days           | Pulse $Q$ with $Q_0 = 500$ and $\delta_Q = 1$days$^{-1}$ |

According to Filippi et al. [10], treatment with IFN-α boosts PD-L1 expression. PD-L1 is a negative costimulatory molecule, so it impairs the ability of APCs to activate T-cells. We therefore set $\nu_{12} = 0$ so CD4s produce no IFN-γ, and $\gamma_C = 0$ so CD8s do not proliferate [10]. Treatment with Tregs is relatively straightforward, directly increasing the $R$ population, which we implement by changing $\alpha_R$.

Fife et al. [9] treat with aPDL1, which we assume should have the opposite effect to IFN-α treatment. We therefore increase $\nu_{12}$ by a factor of 10 and set $\gamma_C$ equal to $\gamma_T$, which is the maximum growth rate of T-cells. Anti-CD3 interferes with the interaction between T-cells and APCs. Thus, we let $\sigma_T = \sigma_R = 0$ to indicate that no division takes place. We also set $\delta_{T2} = 0$ and $\delta_{T1} = .1$, which is equivalent to the assumption that both effectors and Tregs die at the IL-2 deprived death rate of $\delta_{T1} + \delta_{T2}$ as there is no source of IL-2.
Finally, to simulate IL-2 treatment we assume that $Q$ obeys

$$Q = Q_0 \sum_{t_i} e^{(t_i - t)\delta_Q} H(t_i - t)$$  \hspace{1cm} (22)$$

$$H(t) = \begin{cases} t & t > 0 \\ 0 & \text{else} \end{cases}$$  \hspace{1cm} (23)$$

where the $t_i$s are spaced every 2 days for the duration of the treatment. This represents pulses of $Q_0$ that decay at a rate of $\delta_Q$ per day. This matches the treatment described in [26].

5. Results

5.1. Magnitude of initial inflammation determines T1D prognosis. As demonstrated in section 2.4, the initiation model [5] and [7] has two stable equilibria, representing insulitis of different severities. By changing the initial conditions, we can shift the long term behavior of the system from mild to severe insulitis and the outcome from nondiabetic to diabetic. Specifically, we hold all initial conditions constant with the exception of activated macrophages. We start each simulation at $t_0 = 14$ days, during the apoptotic wave. The initial number of activated macrophages, $M^*(t_0)$, will change depending on severity of the wave, which could vary between mice. Figure 4 shows time series for $M^*(t_0) = 1.6 \times 10^7$ cells (Figure 4A,B) and $M^*(t_0) = 8 \times 10^6$ cells (Figure 4C,D). When $M^*(t_0)$ is high, the CD4 and macrophage populations equilibrate relatively rapidly to the severe insulitis state (Figure 4A), eventually leading to T1D onset (Glucose $>$ 250mg/dl) at 16 weeks (Figure 4C). When $M^*(t_0)$ is low, the CD4 and macrophage populations equilibrate to the mild insulitis state (Figure 4C), and T1D does not develop (Figure 4D).

5.2. Simulation of mouse populations. One of the main goals of this study is to model the incidence of T1D in NOD mice under various treatments. Not all NOD mice develop T1D, and the age of onset can vary among those that do. As our ODE model is deterministic, we represent the differences between individuals via parameter values and initial conditions. To simulate experiments with groups of $N$ mice, we make $N$ parameter sets, sampling each parameter from a different distribution, described below. We then replicate those parameter sets and initial conditions for each treatment, so differences between treatments are never due to stochasticity. We start each simulation at the time of the initial inflammation ($t_0 = 14$ days). Therefore, we assume that the number of activated macrophages will initially be elevated in each mouse, as our model does not include the initiating event. The initial macrophage population could be different for each mouse due to diet or differences in development. We draw this value from the normal distribution $(1.2 + N(.4,1)) \times 10^7$ cells. Likewise, the value $\eta_8$ is dependent on the affinity of CD8s for $\beta$-cells and is therefore the outcome of a complicated process of gene rearrangement, thymic selection, and the population dynamics of competing CD8 clones. Where specified, we generate this value from the log-normal distribution $3.2 \times 10^{-13}10^N(0,1/9)\text{days}^{-1}$. We generate all other parameters by sampling from a log-normal distribution with the means.
5.3. **Treatment with IL-2 increases Treg:Teff ratio and prevents T1D.** Several groups [15, 26] find that treatment with exogenous IL-2 can restore the Treg population and prevent the development of T1D. We treat groups of 100 mice with 1, 5, or 11 weeks of IL-2 pulses (of 500 every 2 days). Treatment for 1 week causes a transient but significant drop in the CD4 population and a corresponding rise in the Treg population (Figure 5A). This results in a very small delay in T1D, but no change in incidence. Treatment for 5 weeks, on the other hand, leads to a permanent decrease in the CD4 and inflammatory macrophage population and a permanent increase in the Treg population. This leads to a very large decrease in incidence (Figure 6). Treatment for 11 weeks has little marginal benefit as compared to 5 weeks. In both of these latter
cases, insulitis is greatly reduced, but remains perpetually. The lower level of insulitis is insufficient, in most cases, to stimulate the growth of a killer CD8, and so T1D never occurs.

**Figure 5.** Simulation of IL-2 treatments of different lengths. Using the baseline parameters, we simulated treatment with IL-2 for 0 (Panel A), 1 (Panel B), 5 (C), or 11 (D) weeks. Each panel shows the time course of the inflammatory macrophages ($M^*$), resting macrophages ($M$), effector CD4s ($T$), and Tregs ($R$). The dosage is $Q = 500$. 

17
5.4. **CD3 induced tolerance requires continued activity of PD-L1.** Fife et al. \[9\] demonstrate that early treatment with an aCD3 prevents T1D. CD3 is a surface protein on T-cells that helps them bind to antigen presenting cells. We can represent CD3 treatment by setting $\sigma_T = \sigma_R = 0$ to indicate that no proliferation takes place. We further modify the death rates of both effectors and Tregs to be $\delta_{T1} + \delta_{T2}$, indicating that they receive no survival signals from the IL-2-BCL pathway. Fife’s group also treats some mice with a PD-L1 antibody. PD-L1 acts as a negative regulator of T-cells. We represent PD-L1 treatment by increasing $\nu_{12}$ 10-fold, corresponding to a decrease in the activation threshold of CD4 T-cells. This change means that CD4 T-cells require 10 times less IL-12 to activate and start to produce IFN-$\gamma$. We also assume that more PD-L1 dramatically increases the division rate of CD8 T-cells to the maximum rate of T-cell division $\gamma_T$.

We follow the same protocol as Fife, treating with aCD3 at 5 weeks and aPD-L1 at 17 weeks, with both treatments lasting for 2 weeks. Our results (Figure 7) match the key features of the experiment. With aCD3 treatment, aPD-L1 accelerates T1D among NOD mice and leads to a much higher incidence. Mice that received aCD3 alone did not develop any T1D, whereas 100% of those that also received aPD-L1 rapidly developed T1D shortly after the latter treatment.

5.5. **Synergy between IFN-$\alpha$ and Tregs.** Filippi et al. \[10\] study the role of viruses in the regulation of T1D in NOD mice. They find that the virus LCMV transiently increases PD-L1 expression. In addition, they hypothesize that the Treg population generated during the immune response may explain the decreased T1D among LCMV treated mice. To test this hypothesis, they treat mice with IFN-$\alpha$, which can also increase PD-L1 expression and transfer Tregs from mice previously exposed to LCMV.

We represent the boost in PD-L1 by setting $\nu_{12} = 0$, meaning that APCs cannot activate CD4 T-cells to produce IFN-$\gamma$, and $\gamma_C = 0$, meaning that CD8 T-cells cannot divide. This is essentially the inverse of how we modeled the aPD-L1 treatment. We represent the injection of T-cells by increasing $\alpha_R$ for the duration of the treatment.

Like Fillipi, we find synergy between the two treatments (Figure 8). The administration of IFN-$\alpha$ by itself does not change the incidence of T1D, but it does delay the age of onset. The administration of Tregs by themselves does not change the age of onset, but does decrease incidence. The combination of both treatments decreases incidence by more than the sum of the individual treatments. All of these observations replicate Fillipi’s findings. In this experiment, we used a smaller range of $\eta_8$ to bring it in line with the other parameters. Without this change, the variance is so large that it obscures the synergy.

5.6. **CD4 and macrophage parameters affect incidence while CD8 parameters affect age of onset.** To determine which parameters contribute to incidence and which to age of onset, we ran a sensitivity analysis for each parameter. First we generate 100 pairs of values of $\eta_8$ and $M^*(t_0)$, our two key parameters. Then we vary each parameter, one at a time, from 50% to 200% of its baseline value, equally spaced on a log scale, with every other parameter fixed at its baseline. For each value of the current parameter, we simulate the system using each of the 100 parameters pairs for $\eta_8$ and $M^*(t_0)$. We record if and when T1D develops in each simulation.
Figures 9, 10, and 11 summarize the results of the sensitivity analysis. In each panel, we vary a different parameter. The blue line shows the incidence, while the red and grey lines show the median and deciles, respectively, of the age of onset. Figure 9 shows parameters that primarily affect age of onset, Figure 10 shows those that primarily affect incidence, and Figure 11 shows those with strong effects on both. In general, the parameters that describe CD4 and macrophage behavior affect only incidence and those that describe CD8 behavior affect only the age of onset. We summarize this pattern in Figure 12 that shows the entire model, with each arrow color-coded and scaled according to its significance. Bolder arrows have greater significance, red arrows affect primarily age of onset, blue
Figure 7. Simulation of treatment of NOD mice with aCD3 and aPDL1. We generated 100 different parameter sets (‘mice’) and simulated each T1D progression under four different simulated treatments. Mice received no treatment, aCD3 at 5 weeks of age, aPDL1 at 17 weeks, or both treatments. This is a replication of experiment from [9].

6. Discussion

In this paper, we present a mathematical model of Type 1 diabetes (T1D) in the NOD mouse. We propose that the intensity of the apoptotic wave controls the eventual development of T1D. We further propose that the long delay between this initial inflammation and the destruction of the islets is due to the growth and maturation of the CD8 population. Therefore, the model has two components: an ‘initiation’ component that consists of equations governing the interaction of CD4s and macrophage populations, and a ‘progression’ component that describes the growth of CD8s, their killing of \( \beta \)-cells, and the eventual rise in blood glucose. The initiation component has two possible outcomes, defined by its
We generated 100 different parameter sets (‘mice’) and simulated each T1D progression under four different simulated treatments. Mice received no treatment, IFN-α at 9 weeks of age, Tregs at 11 weeks or both treatments. This is a replication of experiment from [10].

stable equilibria, only one of which leads to T1D. These equilibria are distinguished by the relative activity of Tregs, effectors, and activated macrophages and their associated cytokines: IL-10, IFN-γ and IL-12.
FIGURE 9. Sensitivity analysis of full model. Parameters that primarily affect age of onset. We vary an individual parameter from 50% to 200% of its baseline value. We hold each other parameter constant except for the killing rate of CD8 $\eta_8$ and the initial number of activated macrophages $M^*(t_0)$. The blue line shows the percentage of diabetic mice, by the end of 50 weeks, in the sample. The red and grey lines show the median and deciles, respectively, of the age of onset.

Our model reproduces the results of several experiments on NOD mice: aCD3 treatment, aPDL1 treatment, IL-2 treatment, IFN-α treatment, and Treg treatment. All of these treatments amount to shifting the trajectory from the basin of attraction of the severe-insulitis state to that of the mild insulitis state. A treatment that does not cause a transition can still cause a delay in insulitis. For example, IFN-α treatment alone does not decrease incidence but does delay T1D due to downstream effects that interfere with the CD8 population. When combined with adoptive transfer of Tregs, it does significantly
Figure 10. Sensitivity analysis of full model. Parameters that primarily affect incidence. We vary an individual parameter from 50% to 200% of its baseline value. For each other parameter, we randomly sample 100 times from a normal distribution centered on the baseline value and run a separate simulation for each parameter set. The blue line shows the percentage of diabetic mice, by the end of 50 weeks, in the sample. The red and grey lines show the median and deciles, respectively, of the age of onset.

decrease incidence. According to our model, each treatment by itself is insufficient to make the transition, and so the system returns to the severe-insulitis state once treatment is over. Conversely, treatment with aPDL1 can shift the system from mild to severe arthritis. We show that aCD3 treatment followed by aPDL1 shifts the system from severe to mild and back to severe again. The equivalence between all of these treatments suggests that the system is ‘memoryless’. A mouse that has been cured with aCD3 should be similar to one cured via the transfer of Tregs or IFN-α. Fife et al. [9] found similarities between aCD3
Figure 11. Sensitivity analysis of full model. Parameters that affect incidence and age of onset. We vary an individual parameter from 50% to 200% of its baseline value. For each other parameter, we randomly sample 100 times from a normal distribution centered on the baseline value and run a separate simulation for each parameter set. The blue line shows the percentage of diabetic mice, by the end of 50 weeks, in the sample. The red and grey lines show the median and deciles, respectively, of the age of onset.

Treated mice and those that received insulin coupled splenocytes that tolerized them to the peptide. Table 3.4 summarizes the experimental results that our model can reproduce.

In our model, Tregs play two separate roles. First, Tregs prevent the killing of β-cells by CD4 T-cells. This is an assumption of the model given that Tregs have been observed to control the extent of infiltration in the islet [6, 8]. Second, Tregs can control the inflammatory state of macrophages and other APCs which in turn prevents the development...
of a CD8 response. Due to IL-2 deficiency in NOD mice, Tregs are at a competitive disadvantage in the islets, favoring a proinflammatory environment. In our model, this proinflammatory environment is manifested in the severe insulitis equilibrium. We find that a moderate increase in IL-2 production can eliminate this equilibrium. Treatment with exogenous IL-2 does not eliminate this equilibrium in the long term, but can shift the system to the mild equilibrium as the other treatments do.

It has been suggested that the Treg population loses either effectiveness [28] or population size [26] over time. Lack of IL-2 uptake by Tregs decreases BCL-2 expression and thus survival. Therefore, the IL-2 deficiency lowers the Treg:effector ratio in NOD islets relative to the spleen and lymph nodes and relative to wild type islets. However, this ratio does not decline as the mouse ages. Bleyer et al. find that it stays constant until disease onset, when it rises slightly [15]. In our model, the Treg:effector ratio stays constant over the progression of T1D and is not significantly different between mice that develop T1D
Table 4. Key behaviors this model can reproduce

| Phenomenon                                      | Source | Outcome |
|-------------------------------------------------|--------|---------|
| T1D at 16 weeks                                 | 2      | Fitted  |
| T1D in 80% of females                           | 5      | Fitted  |
| T1D rapid without Tregs                         | 6 and 8|         |
| Protection from T1D with enhanced IL-2 production| 23     |         |
| Protection from T1D with exogenous IL-2         | 23     |         |
| Protection from T1D with anti-CD3 treatment     | 9      |         |
| Protection from T1D with Treg treatment         | 10     |         |
| Delay of T1D with IFN-α treatment               | 10     |         |
| Synergy between Treg and IFN-α treatments       | 10     |         |
| NOD8.3 have faster onset, same incidence        | 31     |         |
| IGRP-specific CD8 predict outcome               | 29     |         |
| Inflammation predicts T1D months in advance     | 12     |         |

and those that do not. This is not to say that the Treg population does not decline in NOD mice, but we need not assume it to reproduce the known phenomena. The presence of T1D-resistant mice, either naturally or following treatment by IL-2, IFN-α, or aCD3, suggests ongoing regulation of the insulitic legion by Tregs. If the Tregs were to intrinsically decline, we would expect all of these mice to also develop T1D. Although this process may happen on a timescale longer than current experiments, it cannot be the driving force behind onset of T1D.

CD8 killer T-cells drive the eventual decline of the β-cell population. Although, in this model, CD4 T-cells also possess the capacity to destroy β-cells, they do not do so in the presence of Tregs (as in 8). The CD8 population in our model represents the population of high affinity CD8 specific to IGRP. Trudeau et al. 29 use the size of this population to predict T1D outcome, and Amrani et al. 4 show that an increase in the average affinity of the CD8 population for IGRP correspond with disease onset. To eliminate the β-cell population, the CD8 population must kill them faster than the β-cells can divide. We estimate that at the time of disease onset, CD8 T-cells kill β-cells at a rate of roughly 16% a day, which is almost 3 times as fast as β-cells have been observed to divide. Therefore, a slight decrease in CD8 number or effectiveness is unlikely to prevent T1D development, although it can slow it. We find that CD8 related parameters primarily contribute to the age of onset instead of T1D incidence. In agreement with this, TCR8.3 NOD transgenic mice that produce only high-affinity IGRP-specific CD8 T-cells have a more rapid onset, but similar incidence to NOD mice 31.

In this model, the treatment of the CD8 population is extremely simple. We only track a single population that grows from a very small number of precursors. In NOD mice, the CD8 population transitions from insulin specific to IGRP specific 4. An initial response to insulin is required for T1D progression 18, but it is unclear whether this is due specifically to the activity of CD8s. It is plausible that initial low levels of β-cell death due to insulin-specific CD8s releases IGRP, which is then presented on APC triggering the switch in autoimmunity. It is also plausible that the CD8-mediated death is necessary
to maintain the ‘severe-insulitis’ state that leads to T1D in this model. One possible experiment to elucidate the role of CD8s would be to create a transgenic line of mice on the NOD background whose CD8s lack the ability to kill $\beta$-cells. According to our simple model of CD8s, they should still develop an IGRP-specific population in the same time frame. If these NOD mice continue to produce primarily insulin-specific CD8s, that will imply that CD8-related pathology drives the progression of their own $\beta$-cell affinity.

Another simplifying assumption of our model is that the $\beta$-cell population responds only to glucose levels and only homeostatically. In fact, $\beta$-cells divide in response to islet inflammation [25]. We have ignored this phenomenon, reasoning that the immune response results in a net decrease in $\beta$-cells. In addition, $\beta$-cells can decompensate [25] when under high demand, producing less insulin per cell. This is due in part to the degranulation of $\beta$-cells during T1D progression [1]. Including any of these phenomena will change the parameter estimates for the immune-mediated killing of $\beta$-cells. More importantly, it could alter some of the conclusions of how we expect the $\beta$-cell population to respond to treatment. For example, the inclusion of degranulated $\beta$-cells could allow for a rapid rebound after IL-2 treatment in new onset mice, as in [15], which cannot be reproduced by the one-compartment $\beta$-cell model we use.

In treating T1D in both NOD mice and humans, there are two main strategies. Administration of anti-inflammatory agents, such as anti-CD3, Vitamin D or omega-3s [16] can reduce insulitis and hopefully prevent the development of an autoimmune destruction. Antigen specific tolerance, such as with oral administration of insulin, aims to delete the autoreactive T-cell clones directly [16, 33]. Only the former have had successful trials among humans, but the latter represent a more specific treatment.

References

[1] E. Akirav, J. A. Kushner, and K. C. Herold. $\beta$-cell mass and Type 1 Diabetes going, going, gone? Diabetes, 57(11):2883–2888, 2008.
[2] T. Alanentalo, A. Hörnblad, S. Mayans, A. K. Nilsson, J. Sharpe, Å. Larefalk, U. Ahlgren, and D. Holmberg. Quantification and three-dimensional imaging of the insulitis-induced destruction of $\beta$-cells in murine type 1 diabetes. Diabetes, 59(7):1756–1764, 2010.
[3] H.K. Alexander and L.M. Wahl. Self-tolerance and autoimmunity in a regulatory T cell model. Bulletin of Mathematical Biology, 73(1):33–71, 2011.
[4] A. Amrani, J. Verdaguer, P. Serra, S. Tafuro, R. Tan, and P. Santamaria. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature, 406(6797):739–742, 2000.
[5] M.S. Anderson and J.A. Bluestone. The NOD mouse: a model of immune dysregulation. Annual Review of Immunology, 23:447–485, 2005.
[6] Z. Chen, A.E. Herman, M. Matos, D. Mathis, and C. Benoist. Where CD4+ CD25+ Treg cells impinge on autoimmune diabetes. The Journal of Experimental Medicine, 202(10):1387–1397, 2005.
[7] B.F. De Blasio, P. Bak, F. Pociot, A.E. Karlsen, and J. Nerup. Onset of type 1 diabetes: a dynamical instability. Diabetes, 48(9):1677–1685, 1999.
[8] M. Feuerer, Y. Shen, D. R. Littman, C. Benoist, and D. Mathis. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity, 31(4):654–664, 2009.
[9] B. T. Fife, I. Guleria, M. G. Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. The Journal of Experimental Medicine, 203(12):2737–2747, 2006.
[10] C.M. Filippi, E.A. Estes, J.E. Oldham, and M.G. Von Herrath. Immunoregulatory mechanisms triggered by viral infections protect from Type 1 Diabetes in mice. The Journal of Clinical Investigation, 119(6):1515, 2009.
[11] M. B. French, J. Allison, D. S. Cram, H. E. Thomas, M. Dempsey-Collier, A. Silva, H. M. Georgiou, L. C. Kay, T. W. and Harrison, and A. M. Lew. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. *Diabetes*, 46(1):34–39, 1997.

[12] W. Fu, G. Wojtkiewicz, R. Weissleder, C. Benoist, and D. Mathis. Early window of diabetes determination in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. *Nature Immunology*, 13(4):361–368, 2012.

[13] N. N. Gorgani, U. Thathaisong, Violet RS Mukaro, O. Pourmpair, A. Tirimacco, C.S.T. Hii, and Antonio Ferrante. Regulation of CRIg expression and phagocytosis in human macrophages by arachidonate, dexamethasone, and cytokines. *The American Journal of Pathology*, 179(3):1310–1318, 2011.

[14] Erica J Graham. *Mathematical models of mechanisms underlying long-term type 2 diabetes progression*. PhD thesis, The University of Utah, 2012.

[15] Yenkel Grinberg-Bleyer, Audrey Baeyens, Sylvaine You, Rima Elhage, Gwladys Fourcade, Sylvie Gregoire, Nicolas Cagnard, Wassila Carpentier, Qizhi Tang, Jeffrey Bluestone, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. *The Journal of Experimental Medicine*, 207(9):1871–1878, 2010.

[16] A. Jayasimhan, K. P. Mansour, and R. M. Slattery. Advances in our understanding of the pathophysiology of Type 1 Diabetes: lessons from the NOD mouse. *Clinical Science*, 126(1):1–18, 2014.

[17] A. Khadra, P. Santamaria, and L. Edelstein-Keshet. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. *Journal of Theoretical Biology*, 256(1):126–141, 2009.

[18] B. Krishnamurthy, N.L. Dudek, M.D. McKenzie, A.W. Purcell, A.G. Brooks, S. Gellert, P.G. Colman, L.C. Harrison, A.M. Lew, and H.E. Thomas. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. *Journal of Clinical Investigation*, 116(12):3258–3265, 2006.

[19] J.M. Mahaffy and L. Edelstein-Keshet. Modeling cyclic waves of circulating T cells in autoimmune diabetes. *SIAM Journal on Applied Mathematics*, 67(4):915–937, 2007.

[20] A.F.M. Marée, R. Kublik, D.T. Finegood, and L. Edelstein-Keshet. Modelling the onset of type 1 diabetes: can impaired macrophage phagocytosis make the difference between health and disease? *Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences*, 364(1842):1267–1282, 2006.

[21] J. Nerup, T. Mandrup-Poulsen, S. Helqvist, H. U. Andersen, F. Pociot, J. I. Reimers, B. G. Cuartero, A. E. Karlsen, U. Bjerre, and T. Lorenzen. On the pathogenesis of IDDM. *Diabetologia*, 37(2):S82–S89, 1994.

[22] S. M. Pop, C. P. Wong, D. A. Culton, S. H. Clarke, and R. Tisch. Single cell analysis shows decreasing FoxP3 and TGFβ1 coexpressing CD4+ CD25+ regulatory T cells during autoimmune diabetes. *The Journal of Experimental Medicine*, 201(8):1333–1346, 2005.

[23] E. Sgouroudis, A. Albanese, and C. A. Piccirillo. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. *The Journal of Immunology*, 181(9):6283–6292, 2008.

[24] N. A. Sherry, J. A. Kushner, M. Glandt, T. Kitamura, A. B. Brilliante, and K. C. Herold. Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes. *Diabetes*, 55(12):3238–3245, 2006.

[25] S. Sreenan, A. J. Pick, M. Levisetti, A. C. Baldwin, W. Pugh, and K. S. Polonsky. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. *Diabetes*, 48(5):989–996, 1999.

[26] Q. Tang, J.Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C.A. Piccirillo, B.L. Salomon, and J.A. Bluestone. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. *Immunity*, 28(5):687–697, 2008.

[27] B. Topp, K. Promislow, G. Devries, R. M. Miura, and D. T. Finegood. A model of β-cell mass, insulin, and glucose kinetics: Pathways to diabetes. *Journal of Theoretical Biology*, 206(4):605–619, 2000.

[28] M. Tritt, E. Sgouroudis, E. d’Hennezel, A. Albanese, and C. A. Piccirillo. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. *Diabetes*, 57(1):113–123, 2008.
[29] J. D. Trudeau, C. Kelly-Smith, C. B. Verchere, J. F. Elliott, J. P. Dutz, D. T. Finegood, P. Santamaria, and R. Tan. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. *Journal of Clinical Investigation*, 111(2):217–223, 2003.

[30] J.D. Trudeau, J.P. Dutz, E. Arany, D.J. Hill, W.E. Fieldus, and D.T. Finegood. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? *Diabetes*, 49(1):1–7, 2000.

[31] J. Verdaguer, D. Schmidt, A. Amrani, B. Anderson, N. Averill, and P. Santamaria. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. *The Journal of Experimental Medicine*, 186(10):1663–1676, 1997.

[32] J. Ye, J. R. Ortaldo, K. Conlon, R. Winkler-Pickett, and H. A. Young. Cellular and molecular mechanisms of IFN-γ production induced by IL-2 and IL-12 in a human NK cell line. *Journal of Leukocyte Biology*, 58(2):225–233, 1995.

[33] L. Zhang, M. Nakayama, and G. S. Eisenbarth. Insulin as an autoantigen in NOD/human diabetes. *Current Opinion in Immunology*, 20(1):111–118, 2008.

[34] Z. J. Zhang, L. Davidson, G. Eisenbarth, and H. L. Weiner. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. *Proceedings of the National Academy of Sciences*, 88(22):10252–10256, 1991.

Department of Mathematics, University of Utah, 155 S 1400 E Rm 233, Salt Lake City, UT 84111, United States
Current address: School of Mathematics, Georgia Institute of Technology, 686 Cherry Street, Atlanta, GA 30332, United States
E-mail address: jmoore323@math.gatech.edu

Department of Mathematics, University of Utah, 155 S 1400 E Rm 233, Salt Lake City, UT 84111, United States
E-mail address: adler@math.utah.edu